Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

Journal of Clinical Investigation

Volumn 117, Issue 9, 2007, Pages 2562-2569

  Shah, Neil P ^a   Skaggs, Brian J ^b   Branford, Susan ^c   Hughes, Timothy P ^c   Nicoll, John M ^b   Paquette, Ronald L ^b   Sawyers, Charles L ^b,d  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA KINASE INHIBITOR; BCR ABL PROTEIN; CARCINOGEN; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; HYBRID PROTEIN; IMATINIB; MUTANT PROTEIN; NILOTINIB; PROTEIN KINASE INHIBITOR;

ALLELE; ANIMAL CELL; ARTICLE; CANCER RELAPSE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG INHIBITION; DRUG SENSITIVITY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GENE MUTATION; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; ONCOGENE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT RESPONSE;

ALLELES; AMINO ACID MOTIFS; ANIMALS; CELL LINE; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FUSION PROTEINS, BCR-ABL; GENOTYPE; HUMANS; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MICE; MUTATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; SENSITIVITY AND SPECIFICITY; THIAZOLES; VALINE;

EID: 34848911943     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI30890     Document Type: Article

References (21)

1. Schindler, T., et al. 2000. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science. 289:1938-1942.
2. Shah, N.P., et al. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2:117-125.
3. Shah, N.P., et al. 2004. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 305:399-401.
4. Lombardo, L.J., et al. 2004. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. 47:6658-6661.
5. Tokarski, J.S., et al. 2006. The structure of dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 66:5790-5797.
6. Gorre, M.E., et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 293:876-880.
7. Weisberg, E., et al. 2005. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 7:129-141.
8. Talpaz, M., et al. 2006. Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. 354:2531-2541.
9. Burgess, M.R., Skaggs, B.J., Shah, N.P., Lee, F.Y., and Sawyers, C.L. 2005. Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl. Acad. Sci. U. S. A. 102:3395-3400.
10. Giles, F.J., et al. 2007. MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation. Blood. 109:500-502.
11. O'Hare, T., et al. 2005. Combined Abl inhibitor therapy for minimizing drug resistance in chronic myeloid leukemia: Src/Abl inhibitors are compatible with imatinib. Clin. Cancer Res. 11:6987-6993.
12. Griswold, I.J., et al. 2006. Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib. Mol. Cell. Biol. 26:6082-6093.
13. Skaggs, B.J., et al. 2006. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants. Proc. Natl. Acad. Sci. U. S. A. 103:19466-19471.
14. Carter, T.A., et al. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. U. S. A. 102:11011-11016.
15. Young, M.A., et al. 2006. Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. 66:1007-1014.
16. Tamborini, E., et al. 2004. A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient. Gastroenterology. 127:294-299.
17. Pao, W., et al. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2:e73.
18. Kobayashi, S., et al. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352:786-792.
19. Michor, F., et al. 2005. Dynamics of chronic myeloid leukaemia. Nature. 435:1267-1270.
20. Branford, S., and Hughes, T. 2006. Diagnosis and monitoring of chronic myeloid leukemia by qualitative and quantitative RT-PCR. Methods Mol. Med. 125:69-92.
21. Branford, S., and Hughes, T. 2006. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods Mol. Med. 125:93-106.